Selected trials utilizing brentuximab vedotin in relapsed/refractory disease
| Regimen . | N . | Median follow-up (months) . | ORR/CR . | ASCT (%) . | PFS . | Reference . |
|---|---|---|---|---|---|---|
| BV combinations | ||||||
| BV-bendamustinex2-6 | 55 | 44.5 | 92.5% ORR 73.6% CR | 74% | 3-year: 60.3% | LaCasce et al Br J Haematol 2020 |
| BV-ICEx2 | 45 | 37 | 91% ORR 74% CR | 75% | 2-year: 80.4% | Lynch et al Lancet Haematol 2021 |
| Sequential BV-ICE | 46 | 20 | 76% CR | 98% | 2-year: 80% | Moskowitz et al Lancet Onc 2015 |
| BV-DHAPx3 | 55 | 27 | 90% ORR | 100% | 2-year: 74% | Kersten et al Haematologica 2021 |
| BRESHAPx3 | 66 | 27 | 91% ORR 70% CR | 70% | 30-month: 71% | Garcia-Sanz et al Ann Oncol 2019 |
| BV-nivolumab | 126 | 24 | 88% ORR 60.7% CR | 36% Included post-ASCT | Not reached | Diefenbach et al. ASH 2023 (abstract) |
| BV-nivolumab | 91 | 34.3 | 85% ORR | 92% | 3-year: 77% (all) 91% (per protocol) | Advani et al Blood 2021 |
| Regimen . | N . | Median follow-up (months) . | ORR/CR . | ASCT (%) . | PFS . | Reference . |
|---|---|---|---|---|---|---|
| BV combinations | ||||||
| BV-bendamustinex2-6 | 55 | 44.5 | 92.5% ORR 73.6% CR | 74% | 3-year: 60.3% | LaCasce et al Br J Haematol 2020 |
| BV-ICEx2 | 45 | 37 | 91% ORR 74% CR | 75% | 2-year: 80.4% | Lynch et al Lancet Haematol 2021 |
| Sequential BV-ICE | 46 | 20 | 76% CR | 98% | 2-year: 80% | Moskowitz et al Lancet Onc 2015 |
| BV-DHAPx3 | 55 | 27 | 90% ORR | 100% | 2-year: 74% | Kersten et al Haematologica 2021 |
| BRESHAPx3 | 66 | 27 | 91% ORR 70% CR | 70% | 30-month: 71% | Garcia-Sanz et al Ann Oncol 2019 |
| BV-nivolumab | 126 | 24 | 88% ORR 60.7% CR | 36% Included post-ASCT | Not reached | Diefenbach et al. ASH 2023 (abstract) |
| BV-nivolumab | 91 | 34.3 | 85% ORR | 92% | 3-year: 77% (all) 91% (per protocol) | Advani et al Blood 2021 |